Showing results (31-40 of 85) with videos related to
Sort By:
Pageof 9
Journal of the Neurological Sciences|November 8, 2017
Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric studyVincent Planche, Xavier Moisset, Remy Morello, et al.Journal of Neurology|February 5, 2011
Cancer and multiple sclerosis in the era of disease-modifying treatmentsChristine Lebrun, Patrick Vermersch, David Brassat, et al.Movement Disorders : Official Journal of the Movement Disorder Society|July 31, 2003
Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissueValérie Cochen, Maria-Joao Ribeiro, Jean-Paul Nguyen, et al.Multiple Sclerosis and Related Disorders|March 17, 2023
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosisLana Zhovtis Ryerson, John F Foley, Gilles Defer, et al.The Lancet. Neurology|April 28, 2022
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trialJohn F Foley, Gilles Defer, Lana Zhovtis Ryerson, et al.Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2013
Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trialDavid Devos, Caroline Moreau, David Maltête, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|September 3, 2016
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled studyAyman Tourbah, Christine Lebrun-Frenay, Gilles Edan, et al.Neurology and Therapy|July 24, 2024
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)Heinz Wiendl, John Foley, Gilles Defer, et al.Neurology and Therapy|December 23, 2022
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert ConsensusJerome De Sèze, Laurent Suchet, Claude Mekies, et al.Neurology(R) Neuroimmunology & Neuroinflammation|October 11, 2024
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple SclerosisJohn F Foley, Gilles Defer, Lana Zhovtis Ryerson, et al.Pageof 9